These are top 10 stocks traded on the Robinhood UK platform in July
Applied Therapeutics Inc (NASDAQ:APLT) stock has plummeted to a 52-week low, reaching a distressing price level of $0.42. According to InvestingPro data, the company’s overall financial health score is rated as WEAK, with particularly concerning metrics in profitability and price momentum. This significant drop reflects a stark contrast to the company’s performance over the past year, with the stock experiencing a precipitous 1-year change, down by -92.55%. Investors have watched with concern as APLT shares have steadily declined, eroding nearly all of their value over the course of the year, and now sit at a level that prompts questions about the company’s future prospects and potential for recovery. The company’s market capitalization has shrunk to just $51.31 million, while analysts have revised their earnings expectations downward. InvestingPro analysis indicates the stock is currently undervalued, though investors should note that three analysts have recently lowered their earnings forecasts for the upcoming period. For deeper insights into APLT’s valuation and 12+ additional ProTips, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Applied Digital Corporation reported fiscal second-quarter results that exceeded analyst expectations, with revenue reaching $63.9 million, a 51% increase year-over-year. The company’s adjusted earnings per share were -$0.06, outperforming the analyst consensus of -$0.14. A significant contributor to this growth was the Cloud Services segment, which saw a revenue surge of 523% year-over-year to $27.7 million. Applied Digital also announced a $5 billion perpetual preferred equity financing facility with Macquarie Asset Management, aiming to strengthen its position in the high-performance computing data center sector.
Meanwhile, Applied Therapeutics is facing a potential delisting from the Nasdaq Stock Market due to non-compliance with the minimum bid price requirement. The company has been given until August 6, 2025, to meet the standard by maintaining a closing bid price of at least $1.00 per share for ten consecutive business days. In another development for Applied Therapeutics, the company appointed Todd F. Baumgartner as the new Chief Regulatory Officer. Dr. Baumgartner brings over 35 years of experience in the pharmaceutical industry and will lead global regulatory strategies at the company. These recent developments highlight significant changes and challenges for both companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.